<DOC>
	<DOCNO>NCT00349349</DOCNO>
	<brief_summary>The purpose study determine whether HuMax-CD20 ( ofatumumab ) effective treatment patient fail fludarabine alemtuzumab .</brief_summary>
	<brief_title>HuMax-CD20 B-Cell Chronic Lymphocytic Leukemia ( B-CLL ) Patients Failing Fludarabine Alemtuzumab</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>1 . Tumor cell phenotype consistent BCLL 2 . Patients active BCLL indication treatment 3 . Failing least one fludarabinecontaining treatment regimen 4 . Failing least one alemtuzumabcontaining treatment regimen 5 . ECOG Performance Status 0 , 1 , 2 6 . Life expectancy least 4 month 1 . Previous treatment alemtuzumab within 6 week prior Visit 2 2 . Previous autologous stem cell transplantation within 6 month prior Visit 2 3 . Allogeneic stem cell transplantation 4 . Radioimmunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>